Tianjin Pharmaceutical Da Ren Tang's (SGX:T14, SHA:600329) profit attributable to owners of the parent was down 16% year over year to 270.4 million yuan in the second quarter of the year from 321.7 million yuan, according to a filing with the Singapore Exchange on Wednesday.
Revenue was down 3% year over year to 1.88 billion yuan from 1.93 billion yuan largely due to a decrease in sale of goods.
Price (SGD): S$2.16, Change: S$-0.07, Percent Change: -3.14%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments